Based on the aggregated intelligence of 115,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant Pfizer (NYSE:PFE) has earned a respected four-star ranking. While five-star stocks have been the best performers, our data has shown that four-star stocks still outshine the market by a significant margin and shouldn't be taken lightly; conversely, low-rated stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Pfizer's business, and see what CAPS investors are saying about the stock right now.

Pfizer facts

Headquarters (Founded)

New York (1849)

Market Cap

$125.79 billion

Industry

Pharmaceuticals

TTM Revenue

$48.84 billion

Management

CEO Jeffrey Kindler
CFO Frank D'Amelio

Return on Equity (average last three years)

14.2%

Competitors

Merck (NYSE:MRK)
Novartis (NYSE:NVS)

CAPS members bullish on PFE also bullish on

General Electric (NYSE:GE)
Johnson & Johnson (NYSE:JNJ)

CAPS members bearish on PFE also bearish on

Citigroup (NYSE:C)
General Motors (NYSE:GM)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, roughly 88% of the 1,106 All-Star members who have rated Pfizer believe the stock will outperform the S&P 500 going forward. These Foolish bulls include TMFHelical and PennyPincher12, both of whom are ranked in the top 4% of our community.

In late July, TMFHelical noted that "Yes a revenue cliff is in the distance, but it isn't that close and in the interim, Lipitor is piling up an awful lot of cash at the base to cushion the fall. Simply too cheap right now."

An earlier pitch from PennyPincher12 in June shares that bullish feeling, focusing on the company's free cash flow-generating qualities:

The business has been growing strong and making a lot of cash, but the stock price is falling. Sooner or later, the value of this company will be reflected in its stock price. Extremely cheap compared to 3 year earnings average in the aggregate, and the dividend will provide income for shareholders even if the stock loses or barely gains in the near time frame. The pharma biz is a good business to be in, and why not invest in the biggest and one of the most profitable companies in the industry?

What do you think about Pfizer, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 115,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Pfizer is a Motley Fool Income Investor and Inside Value recommendation. Johnson & Johnson is also a choice of Income Investor. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool's disclosure policy always gets a perfect score.